Table A2.
Baseline ECOG PS | Primary Malignancy | Cause of Death | Time Since First Dose of Study Drug (weeks) | Time Since Initial Diagnosis (weeks) |
---|---|---|---|---|
0 | Esophageal | PD | 14.1 | 54.2 |
0 | Gastric | PD | 12.6 | 14.3 |
0 | Gastric | PD | 14.7 | 33.7 |
0 | Pancreatic | GI perforation (attributed to capecitabine and sunitinib) | 23.0 | 91.4 |
0 | Unknown primary | Acute renal failure (attributed to disease under study) | 5.6 | 21.7 |
1 | Unknown primary | PD | 6.6 | 46.5 |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status; PD, progressive disease.